Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Main Sequence is a venture capital firm established in 2017 and based in Australia. Founded by CSIRO, Australia's national science agency, it manages over $1 billion in capital, including the CSIRO Innovation Fund. The firm has invested in 51 companies, focusing on bridging the gap between research and industry.
Main Sequence invests in deep technology companies from seed to Series B stages, targeting sectors such as space, healthcare, industrial productivity, and sustainable agriculture. Their investment thesis emphasizes addressing significant global challenges like decarbonization and food security, with a commitment to supporting innovations that tackle these issues.
Notable companies in Main Sequence's portfolio include Terria, which develops advanced mapping and digital twin technologies; Loam Bio, focusing on microbial technology for carbon capture in agricultural soils; and Coviu, an innovator in telehealth solutions. Cylite has achieved a material return for investors through advancements in eye health.
Submit your pitch through their form at https://mseq.vc.
Yes, Main Sequence often leads investment rounds, particularly in their focus areas of deep technology.
The firm is open to follow-on investments, especially for companies that align with their key challenge areas and demonstrate growth potential.
Main Sequence manages over $1 billion in capital, which includes the CSIRO Innovation Fund.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.